Independent association of osteoprotegerin with cardio-vascular damage while chronic kidney disease III–V stages

Mikhail Sopoev; Tamara Bestaeva; Fatima Dzgoeva

doi:doi:10.12737/11811

Independent association of osteoprotegerin with cardio-vascular damage while chronic kidney disease III–V stages

Published в Vladikavkaz Medico-Biological Bulletin · Volume 20, Issue 29, 2014 · Pages 83–89 · Rubrics: Research and development are new medical technologies

DOI 10.12737/11811

Received: 26.06.2015 Accepted: 09.08.2015 Published: 09.08.2015 Language of publication: RUS

Authors

Mikhail Sopoev · Tamara Bestaeva · Fatima Dzgoeva

ABSTRACT

To detect the pathophysiologic link between osteoprotegerin with myocardial failare in chronic kidney disease (СКD) stages III–V was the aim of his research. Osteoprotegerin was measured using commercially kits in 72 CKD stages III–V patients (40 females and 35 males aged 34–67 years). The patients were examined clinically with estimation of the levels of calcium, phosphorus parathormone. Echocardiography on Aloka-4000 unit was made. Left ventricular geometry was assessed by J.Gottdiener classification. Therapy included the correction of anemia, arterial hypertension and phosphorus-calcium metabolism. Mean age of patients was 48±6 years, mean systolic and diastolic blood pressures were 161±22/81±11 mm Hg. Osteoprotegerin high level correlated with renal function and severity of left ventricular hypertrophy. We have shown that the changes of mediator of mineral-bone metabolism osteoprotegerin induced by CKD are independently associated with cardiovascular disfunction.

KEYWORDS

osteoprotegerin PTH calcification pressure postloading mineral-bone disorder.

Information References

Authors:

Type:

Article

Pages:

from 83 to 89

Status:

Published

Language:

Russian

Keywords:

osteoprotegerin, PTH, calcification, pressure, postloading, mineral-bone disorder.

References

1. Batyushin M. M., Vrublevskaya N. S., Terent´ev V. P. Prognozirovanie techeniya khronicheskoy serdechnoy nedostatochnosti, oslozhnivsheysya razvitiem pochechnoy disfunktsii. Klinicheskaya nefrologiya, 2010. Vyp. 5.S. 41-44.

2. Dzgoeva F. U., Gatagonova T. M., Kadzaeva Z. K. Diastolicheskaya disfunktsiya pri razlichnykh variantakh gipertrofii levogo zheludochka u bol´nykh s terminal´noy stadiey pochechnoy nedostatochnosti. Terapevticheskiy arkhiv, 2013. Vyp. 12. S. 19-24

3. Dzgoeva F. U. i dr. Diastolicheskaya disfunktsiya pri razlichnykh variantakh gipertrofii levogo zheludochka u bol´nykh s terminal´noy stadiey pochechnoy nedostatochnosti. Kardioprotektivnoe deystvie eritropoetina. Vladikavkazskiy mediko-biologicheskiy vestnik, 2013. T. 16. S. 114-121.

4. Milovanova L. Yu. i dr. Novye markery kardiorenal´nykh vzaimosvyazey pri khronicheskoy bolezni pochek. Terapevticheskiy arkhiv, 2013. Vyp. 6. S. 17-24.

5. Mukhin N. A. Khronicheskaya bolezn´ pochek. Klinicheskaya farmakologiya i terapiya, 2011. Vyp. 4. S. 70-75.

6. Smirnov A. V. Sistemnyy podkhod k analizu kardiorenal´nykh vzaimootnosheniy kak pervyy shag na puti k nefrologii formata. Nefrologiya, 2011. Vyp. 15. Razdel 2. S. 11-19.

7. Cozzolino M. et al. Vascular calcification in chronic kidney disease. EMJ Nephrology, 2013. Vol. 1. P. 46-51.

8. Cozzolino M. et al. The Ratio of Osteoprotegerin to Fetuin-A Is Independently Associated with Vascular Stiffness in Hemodialysis Patients. Nephron Clinical Practice, 2013. Vol. 12. P. 165-172.

9. Hisu H. J., Wun M. Fibroblast growght factor-23: a possible cause of left ventricular hypertrophy in hemodialysis patients. Am. J. Medical Sci., 2009. Vol. 30. P. 116-122.

10. Inoue N. et al. Aortic pulse wave velocity predicts cardiovascular mortality in middle-aged and elderly. Japanese medical, 2009. Vol. 73. P. 549-553.

11. Guzel S. et al. Osteoprotegerin, leptin and IL-6: Association with silent myocardial ischemia in type 2 diabetes mellitus. Diabetes and Vascular Disease Research, 2013. Vol. 10. P. 25-31.

12. Kurnatowska I. et al. Serum osteoprotegerin is a predictor of progression of atherosclerosis and coronary calcification in hemodialysis patients. Nephron Clinical Practice, 2011. Vol. 11. P. 297-304.

13. Mogelvang R. et al. Comparison of osteoprotegerin to traditional atherosclerotic risk factors and high-sensitivity C reactive protein for diagnosis of atherosclerosis. Am. J. Cardiology, 2012. Vol. 19. P. 15-20.

14. Ozkok A. et al. Osteoprotegerin/RANKL Axis and Progression of Coronary Artery Calcification in Hemodialysis Patients. JASN, 2012. Vol. 7. P. 965-973.

15. Shave R. et al. Exercise-induced cardiac troponin elevation: evidence ,mechanisms and implication. J. Am.Coll. Cardiology, 2010. Vol. 16. P. 169-176.

16. Sigrist M. K. et al. Elevated osteoprotegerin is associated with all-cause mortality in CKD stage 4 and 5 patients in addition to vascular calcification. Nephrology. Dialysis. Transplantation, 2009. Vol. 24. P. 3157-3162.

17. Smith E. R. et al. Serum Calcification Propensity Predicts All-Cause Mortality in Predialysis CKD. JASN, 2014. Vol. 25: P. 339-348.

18. Speer G. et al. Serum osteoprotegerin level, carotid-femoral pulse wave velocity and cardiovascular survival in haemodialysis patients. Nephrology. Dialysis. Transplantation, 2008. Vol. 23. P. 3256-3262.

19. Winther S. et al. Osteoprotegerin is associated with all-cause mortality in CKD stage 4 and 5 patients in addition to vascular calcification. Clinical Nephrology, 2013. Vol. 80. P. 161-167.

Доступ и загрузка

🗂 JATS XML ❝ To cite 📎 Citations

—

Views

—

Downloads

Citations

Индексируется в

Independent association of osteoprotegerin with cardio-vascular damage while chronic kidney disease III–V stages

Confirmation

Регистрация